India Ratings Upgrades Glenmark Pharmaceuticals’ Long-Term Bank Loans to 'IND AA+'/Stable
Glenmark Pharmaceuticals Ltd · Others (Uncategorized) · 11 Sept 2026, 2:15 pm
India Ratings Upgrades Glenmark Pharmaceuticals’ Long-Term Bank Loans to 'IND AA+'/Stable India Ratings upgraded Glenmark Pharmaceuticals Ltd’s long-term bank loans to ‘IND AA+’/Stable from ‘IND AA’ on 10th Sep'26, driven by balance sheet deleveraging and reduced innovation funding needs following subsidiary IGI's USD700 million ISB 2001 licensing deal with AbbVie. Glenmark recognized USD560 million in FY26, enabling zero gross debt, negative net adjusted leverage of -0.13x, and FY26 EBITDA margin expansion to 26.9%. Management targets FY27 revenue of INR170 billion–INR180 billion and 21%–22% EBITDA margins, supported by Ryaltris expansion and US recovery.
Original exchange filing (PDF)
More announcements from Glenmark Pharmaceuticals Ltd
- Ichnos Glenmark Innovation (IGI) announces IND submission to US FDA for ISB 2301 · 18 Nov 2026
- Glenmark Pharmaceuticals Inc., USA Launches Authorised Generic of INLYTA (axitinib) Tablets, 1 mg and 5mg · 16 Nov 2026
- Schedule of Schedule of Analyst/ Institutional Investor Meetings · 10 Nov 2026
- Initmation of Schedule of Analyst/ Institutional Investor Meetings · 10 Nov 2026
- Intimation of Schedule of Analyst/ Institutional Investor Meetings · 10 Nov 2026
- Intimation of Schedule of Analyst / Institutional Investor Meetings · 10 Nov 2026
- Transcript of the Earnings Call · 09 Nov 2026
- Audio recording of Q2 FY 2026-27 Earnings Call held on November 06, 2026 · 06 Nov 2026
